SAGE Therapeutics, Inc. is a Pharmaceuticals company based in the United States of America with a medium risk ESG score of 22.3. Specializing in brain health medicines, SAGE targets diseases and disorders of the brain with a focus on depression, neurology, and neuropsychiatry. The company's key areas of focus include GABA and NMDA receptor systems within the central nervous system. Their products include ZURZUVAE for postpartum depression in adults and ZULRESSO for individuals 15 years and older. SAGE also has a pipeline of other drugs such as SAGE-324 and Dalzanemdor (SAGE-718).